These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37354473)

  • 1. The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement.
    Chopra HK; Wander GS; Ponde CK; Nanda NC; Khullar D; Venugopal K; Ray S; Nair T; Rana DS; Kher V; S Sawhney JP; Kasliwa RR; Jabir A; Chakraborty R; Chandra P; Bansal S; Kumar V; Pancholia AK; Kapoor A; Prakash S; Saxena A; Rastogi V; Sharma V; Arora YK; Dasbiswas A; Bhargava M; Jaswal A; Bhargava K; Bhatia M; Omar AK; Khanna NN; Passey R; Bhalla D; Vijayalakshmi IB; Bhalla AK; Moorthy A; Isser HS; Mishra SS; Routray SN; Tandon V; Sinha A; Bansal M; Jain P; Hotchandani R; Jain D; Katyal VK; Gulati S; Tandon R; Jaggi S; Sehgal B; Gupta V; Mehrotra R; Krishnamani NC; Pathak SN; Yadav MS; Chawla R; Pal J; Chatterjee N; Samajdar SS; Shastry NR
    J Assoc Physicians India; 2023 Feb; 71(2):11-12. PubMed ID: 37354473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice.
    Davis LE; Pogge EK
    Ann Pharmacother; 2022 May; 56(5):548-555. PubMed ID: 34459280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
    Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
    J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease.
    Niu CY; Yang SF; Ou SM; Wu CH; Huang PH; Hung CL; Lin CC; Li SY
    J Am Heart Assoc; 2022 Sep; 11(18):e026407. PubMed ID: 36062622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
    Ekici B; Yaman M; Küçük M; Dereli S; Yenerçağ M; Yiğit Z; Baş MM; Karavelioğlu Y; Çakmak HA; Kıvrak T; Özkan H; Altın C; Şabanoğlu C; Demirkan B; Ataş AE; Kılıçaslan F; Altay H; Tengiz İ; Fahri Erkan A; Kılıçaslan B; Olgun FE; Durakoğlugil ME; Alhan A; Zoghi M
    Turk Kardiyol Dern Ars; 2021 Jul; 49(5):357-367. PubMed ID: 34308869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.